Grail collaborates with VA on Galleri study

By LabPulse.com staff writers

June 1, 2022 -- Grail is collaborating with the U.S. Department of Veterans Affairs (VA) Health Administration on a large-scale observational study assessing the performance of its Galleri multicancer early-detection blood test.

Over the next three years, 10,000 veterans across the U.S. will receive Galleri and be able to enroll in the company's Reflection registry. The VA Pittsburgh Healthcare System will be the first of approximately 10 VA sites that will participate in the study, according to Grail.

Intermountain Healthcare to offer Galleri cancer blood test
Utah-based health system Intermountain Healthcare will be offering Grail’s Galleri multicancer early detection blood test as a complement to existing...
Grail to partner with Premier
Grail has signed a collaborative agreement with Premier to use that company's PINC AI technology and services platform to expand patient access to Grail's...
Illumina completes Grail deal, despite lack of European approval
Illumina has completed its acquisition of cancer diagnostics developer Grail, almost a year after announcing the deal. Illumina said it would run Grail...
Group forms to evaluate early cancer detection tests
A group of more than 35 clinical researchers, academic institutions, healthcare provider organizations, patient advocacy groups, and private companies...
Grail teams with Quest on blood test for early cancer detection
Cancer diagnostics startup Grail has signed Quest Diagnostics to provide phlebotomy services for its upcoming Galleri multicancer early detection blood...

Copyright © 2022 LabPulse.com

Last Updated lo 6/2/2022 7:31:58 AM